Results 11 to 20 of about 5,708 (209)

Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response [PDF]

npj Vaccines, 2021
Current influenza vaccines have a suboptimal effectiveness. The introduction of a novel A/H1N1 influenza virus in 2009 (H1N1pdm09) provided a unique opportunity to study the humoral response to the AS03-adjuvanted H1N1pdm09 vaccine and repeated annual ...
Anders Madsen, Åsne Jul-Larsen, Mai-Chi Trieu, Florian Krammer, Rebecca J. Cox   +4 more
doaj   +6 more sources

Efficacy of Immunostimulatory Adjuvants and Nano‐Adjuvants in Current SARS‐CoV‐2 Vaccines: A Comprehensive Review [PDF]

Health Science Reports
Background and Aims SARS‐CoV‐2 continues to pose global challenges, and current vaccines face limitations (variant escape, waning immunity). This review evaluates immunostimulatory adjuvants and nano‐adjuvants to enhance immune responses and optimize ...
Peyman Kheirandish Zarandi, Mohammad Reza Zinatizadeh, Mohsen Ghiasi, Mohammad Rezaei Zadeh Rukerd, Hanieh Mirkamali, Ehsan Shokri   +5 more
doaj   +3 more sources

AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans. [PDF]

Sci Immunol
Vaccine adjuvants increase the breadth of serum antibody responses, but whether this is due to the generation of antigen-specific B cell clones with distinct specificities or the maturation of memory B cell clones that produce broadly cross-reactive ...
Grigoryan L, Feng Y, Bellusci L, Lai L, Wali B, Ellis M, Yuan M, Arunachalam PS, Hu M, Kowli S, Gupta S, Maysel-Auslender S, Maecker HT, Samaha H, Rouphael N, Wilson IA, Moreno AC, Suthar MS, Khurana S, Pillet S, Charland N, Ward BJ, Pulendran B.   +22 more
europepmc   +2 more sources

Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination.

PLoS ONE, 2015
Type 1 narcolepsy is caused by deficiency of hypothalamic orexin/hypocretin. An autoimmune basis is suspected, but no specific antibodies, either causative or as biomarkers, have been identified. However, the AS03 adjuvanted split virion H1N1 (H1N1-AS03)
Simon Thebault, Patrick Waters, Matthew D Snape, Dominic Cottrell, Niklas Darin, Tove Hallböök, Anne Huutoniemi, Markku Partinen, Andrew J Pollard, Angela Vincent   +9 more
doaj   +5 more sources

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities

npj Vaccines, 2022
The rapid spread of SARS-CoV-2 continues to impact humanity on a global scale with rising total morbidity and mortality. Despite the development of several effective vaccines, new products are needed to supply ongoing demand and to fight variants.
Nathalie Charland, Philipe Gobeil, Stéphane Pillet, Iohann Boulay, Annie Séguin, Alexander Makarkov, Gretchen Heizer, Kapil Bhutada, Asif Mahmood, Sonia Trépanier, Karen Hager, Julia Jiang-Wright, Judith Atkins, Pooja Saxena, Matthew P. Cheng, Donald C. Vinh, Philippe Boutet, François Roman, Robbert Van Der Most, Maria Angeles Ceregido, Marc Dionne, Guy Tellier, Jean-Sébastien Gauthier, Brandon Essink, Michael Libman, Jason Haffizulla, André Fréchette, Marc-André D’Aoust, Nathalie Landry, Brian J. Ward   +29 more
doaj   +2 more sources

Immunogenicity and Safety of AS03-Adjuvanted H7N9 Influenza Vaccine in Adults (18-64 and ≥65 Years): A Phase 1/2, Randomized, Placebo-Controlled Trial. [PDF]

Influenza Other Respir Viruses
Influenza A/Hong Kong/125/2017 (H7N9) virus poses a pandemic risk owing to its evolving nature. This study evaluated the immunogenicity and safety of an AS03‐adjuvanted H7N9 vaccine in adults (18–64 years [younger] and ≥65 years [older]).
Hastie A, Clarke T, Germain S, Ollinger T, Lese P, Gupta V.   +5 more
europepmc   +2 more sources

Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine

Science Translational Medicine, 2023
The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that evade immunity elicited by vaccination has placed an imperative on the development of countermeasures that provide broad protection against SARS-CoV-2 and ...
Yupeng Feng, M. Yuan, J. Powers, Mengyun Hu, J. Munt, P. Arunachalam, S. Leist, L. Bellusci, Junghyun Kim, Kaitlin R. Sprouse, Lily E. Adams, Sumana Sundaramurthy, Xueyong Zhu, Lisa M. Shirreff, M. Mallory, Trevor D. Scobey, Alberto Moreno, D. O’hagan, H. Kleanthous, F. Villinger, D. Veesler, N. King, M. Suthar, S. Khurana, R. Baric, I. Wilson, B. Pulendran   +26 more
semanticscholar   +3 more sources

Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques

npj Vaccines, 2023
Despite the availability of several effective SARS-CoV-2 vaccines, additional vaccines will be required for optimal global vaccination. In this study, we investigate the immunogenicity and protective efficacy of the GBP510 protein subunit vaccine ...
Catherine Jacob-Dolan, Jingyou Yu, Katherine McMahan, Victoria Giffin, Abishek Chandrashekar, Amanda J. Martinot, Tochi Anioke, Olivia C. Powers, Kevin Hall, David Hope, Jessica Miller, Nichole P. Hachmann, Benjamin Chung, Sarah Gardner, Daniel Sellers, Julia Barrett, Mark G. Lewis, Hanne Andersen, Harry Kleanthous, Ki-Woen Seo, Su Jeen Lee, Yong Wook Park, Hun Kim, Dan H. Barouch   +23 more
doaj   +3 more sources

AS03- and MF59-Adjuvanted Influenza Vaccines in Children [PDF]

Frontiers in Immunology, 2017
Influenza is a major cause of respiratory disease leading to hospitalization in young children. However, seasonal trivalent influenza vaccines (TIVs) have been shown to be ineffective and poorly immunogenic in this population.
Amanda L. Wilkins, Dmitri Kazmin, Giorgio Napolitani, Elizabeth A. Clutterbuck, Bali Pulendran, Bali Pulendran, Bali Pulendran, Bali Pulendran, Claire-Anne Siegrist, Andrew J. Pollard   +9 more
doaj   +4 more sources

A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. [PDF]

Clin Infect Dis
INTRODUCTION A surge of human influenza A(H7N9) cases began in 2016 in China due to an antigenically distinct lineage. Data are needed about the safety and immunogenicity of 2013 and 2017 A(H7N9) inactivated influenza vaccines (IIVs) and the effects of ...
Rostad CA, Atmar RL, Walter EB, Frey S, Meier JL, Sherman AC, Lai L, Tsong R, Kao CM, Raabe V, El Sahly HM, Keitel WA, Whitaker JA, Smith MJ, Schmader KE, Swamy GK, Abate G, Winokur P, Buchanan W, Cross K, Wegel A, Xu Y, Yildirim I, Kamidani S, Rouphael N, Roberts PC, Mulligan MJ, Anderson EJ.   +27 more
europepmc   +2 more sources